This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Testosterone therapy
(TTh)

Overview

Testosterone deficiency (TD) is treatable.1

The aim of TTh is to restore testosterone levels to the normal physiological range and to improve symptoms of TD. Symptoms associated with TD such as reduced bone mineral density, or poor glycaemic control, may not be directly visible to the patient and may require additional monitoring to see improvements.

Treatment of TD can provide both psychological and physical benefits to patients, resulting in improvements in their overall wellbeing and quality of life. Normalisation of testosterone levels with TTh has also been shown to decrease all-cause mortality and cardiovascular disease risk, compared to patients left untreated.2

References

  1. Hackett G, Kirby M, Edwards D, et al. UK policy statements on testosterone deficiency. Int J Clin Pract. 2017;71(3–4:e12901).
  2. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706–2715.

TES/2022/045. February 2023.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: pharmacovigilance@besins-healthcare.com

Where next...